Cited 0 times in Scipus Cited Count

P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer.

DC Field Value Language
dc.contributor.authorChung, HC-
dc.contributor.authorRha, SY-
dc.contributor.authorKim, JH-
dc.contributor.authorRoh, JK-
dc.contributor.authorMin, JS-
dc.contributor.authorLee, KS-
dc.contributor.authorKim, BS-
dc.contributor.authorLee, KB-
dc.date.accessioned2011-08-24-
dc.date.available2011-08-24-
dc.date.issued1997-
dc.identifier.issn0167-6806-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/3906-
dc.description.abstractExpression and clinical relevance of p-glycoprotein (p-gp) were evaluated in 31 cases of locally advanced breast cancer and 9 cases involving inflammatory breast cancer after induction chemotherapy. The de novo p-gp expression rate was 26% and increased up to 58% (p = 0.03) with the FAC (5-fluorouracil, adriamycin, cyclophosphamide) regimen. Although more clinically complete responders were found in the secondary p-gp negative group (p = 0.02), this difference was not found in pathological tumor response. Moreover, as the grade of the secondary p-gp expression increased, the chemotherapeutic effect decreased, suggesting an inverse relationship between p-gp expression and drug effect (p = 0.04). When we subgrouped the patients into 4 groups using these two parameters, p-gp negative patients presenting with a high drug effect showed a low recurrence rate (p = 0.05) and marginal survival benefits (p = 0.09) as opposed to patients with a low drug effect. But in p-gp positive groups, the recurrence rate was the same between the two groups regardless of the drug effect. Thus, in the p-gp negative patient with a high drug effect, adjuvant chemotherapy with the same regimen as induction chemotherapy may induce more prognostically favorable results. Therefore, clinical application of the secondary p-gp detection can be used as an intermediate endpoint in evaluating drug response for an induction regimen.-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols-
dc.subject.MESHBreast Neoplasms-
dc.subject.MESHCarcinoma, Ductal, Breast-
dc.subject.MESHChemotherapy, Adjuvant-
dc.subject.MESHCyclophosphamide-
dc.subject.MESHDoxorubicin-
dc.subject.MESHDrug Resistance, Multiple-
dc.subject.MESHDrug Resistance, Neoplasm-
dc.subject.MESHFemale-
dc.subject.MESHFluorouracil-
dc.subject.MESHHumans-
dc.subject.MESHImmunohistochemistry-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHP-Glycoprotein-
dc.titleP-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer.-
dc.typeArticle-
dc.identifier.pmid9116319-
dc.identifier.urlhttp://www.kluweronline.com/art.pdf?issn=0167-6806&volume=42&page=65-
dc.contributor.affiliatedAuthor이, 기범-
dc.type.localJournal Papers-
dc.citation.titleBreast cancer research and treatment-
dc.citation.volume42-
dc.citation.number1-
dc.citation.date1997-
dc.citation.startPage65-
dc.citation.endPage72-
dc.identifier.bibliographicCitationBreast cancer research and treatment, 42(1). : 65-72, 1997-
dc.identifier.eissn1573-7217-
dc.relation.journalidJ001676806-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse